..however, after a second dose there is only a... - CLL Support

CLL Support

23,335 members40,040 posts

..however, after a second dose there is only a small and non-significant reduction in vaccine effectiveness

zaax profile image
zaax
18 Replies

In most clinical risk groups, immune response to vaccination is maintained and high levels of VE are seen with both the Pfizer and AstraZeneca vaccines. Reduced antibody response and vaccine effectiveness were seen after one dose of vaccine among the immunosuppressed group, however, after a second dose there is only a small and non-significant reduction in vaccine effectiveness. These findings would support maximising coverage with two doses in immunosuppressed individuals

gov.uk/government/news/covi...

Written by
zaax profile image
zaax
To view profiles and participate in discussions please or .
Read more about...
18 Replies
Parramatta profile image
Parramatta

Hello Zaax, thank you for the interesting read. I sincerely hope the information is accurate.

RosettaClapp profile image
RosettaClapp in reply toParramatta

I doubt it is accurate as it was only 9 people and who knows whether they were on active treatment, in remission or W&W sadly I dont think us on treatment have much cover even if we have had 2 jabs ..going by several peer reviewed bits i have read so far ..I think this is government propaganda

LeoPa profile image
LeoPa in reply toRosettaClapp

Isn't it that treatment helps with t cell exhaustion and perhaps the t cells thus can offer a protection that can make or break a recovery? Life will tell how many vaccinated immune compromised will succumb to covid. It's all guesswork for now.

ChristyAnne_UK profile image
ChristyAnne_UK in reply toParramatta

This has already been the subject of controversy, and the PHE replaced this release with a more accurate one.

RosettaClapp profile image
RosettaClapp in reply toChristyAnne_UK

it only lasted one bbc broadcast as far as I heard !! before those that really know a thing or two about immuno supressed challenged it and it was withdrawn ...

Mijoed profile image
Mijoed

It would seem that, on one hand, they say there is a nonsignificant reduction in vaccine effectiveness within the immunosuppressed group but, on the other, the response may not be as good.

But….Within these clinical risk groups, there will be people with more severe forms of illness – particularly in the immunosuppressed group – who may not respond as well to the vaccines, and we recommend they seek advice from their specialists.

And….

If the planned booster programme goes ahead, the JCVI has recommended that immunosuppressed adults and their household contacts should also be among the first to be offered a third dose of vaccine in September.

bkoffman profile image
bkoffmanCLL CURE Hero

There are so many problems with this government statement it's hard to know where to begin,. Vaccine protect is at best unpredictable in CLL. Other immune compromised groups, ie HIV+ on ARD do fine. Lumping us together is a terrible abuse of data.

bennevisplace profile image
bennevisplace in reply tobkoffman

Exactly. And patient numbers were small.

I'm not into conspiracy theories but it's almost as if PHE were handed the answer beforehand and told to come up with some supporting data.

bennevisplace profile image
bennevisplace

This PHE study is highly suspect when it comes to immunosuppressed.

RosettaClapp profile image
RosettaClapp in reply tobennevisplace

9 people in it evidently ....hardly a comprehensive example of all the different reasons for immune suppression

RosettaClapp profile image
RosettaClapp

As I read the Birmingham study which was a few more than 9 individuals the VE isnt that good sadly

bennevisplace profile image
bennevisplace in reply toRosettaClapp

The Birmingham study has its own issues, but at least it's independent.

Tune in later for an update! healthunlocked.com/cllsuppo...

bennevisplace profile image
bennevisplace in reply toRosettaClapp

If you did tune in, you'll have heard Dr Helen Parry's sceptical assessment of those numbers from PHE.

RosettaClapp profile image
RosettaClapp in reply tobennevisplace

I missed it :( but I did read their preliminary report on their study .and extrapolated from that ..Im just very please that at least someone is batting on our side since the government certainly are not sadly

bennevisplace profile image
bennevisplace in reply toRosettaClapp

She's a scientist, so her assessment can be considered neutral. The video should be out soon.

RosettaClapp profile image
RosettaClapp in reply tobennevisplace

Just had a letter from her with results ...sadly it doesnt mention obinutumazab or venetoclax apart from there not being enough people on it to show any results

bennevisplace profile image
bennevisplace in reply toRosettaClapp

Results - aggregate not yours I take it?

The video is out

healthunlocked.com/cllsuppo...

Treatment with Obinutuzumab impairs Ab production for some while unfortunately. The Israeli study found no antibodies in any participants who'd been on a CD20 Ab less than 12 months before vaccination.

RosettaClapp profile image
RosettaClapp in reply tobennevisplace

Sadly so ..no not my results as far as I know :) but I did participate and I have not long finishe obutumazab abs am continuing with venetoclax ...

Not what you're looking for?

You may also like...

What do all these Vaccine Efficacy Numbers that they quote actually mean?

Efficacy is a crucial concept in vaccine trials, but it’s also a tricky one. If a vaccine has an...
Jm954 profile image
Administrator

NCCN Provides Major Update to COVID-19 Vaccination Recommendations

The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of 32 leading cancer...

CDC OKs COVID-19 vaccine, allows older adults and immunocompromised adults to get second dose Bi Valent vaccine on Wednesday, April 19, 2023

CDC simplifies COVID-19 vaccine recommendations, allows older USA adults and immunocompromised...
lankisterguy profile image
Volunteer

UK first to trial AstraZeneca 'antibody cocktail' aimed at non-vaccine patients

I'm not recruiting for Astrazeneca, but news broke this morning that they are to start phase 3...

Humoral and cellular responses after a third dose of BNT162b2vaccine in patients with lymphoid malignancies

https://assets.researchsquare.com/files/rs-727941/v1/4e8668e3-2c97-4a91-8334-dd0258b8e2ed.pdf...
JIDD profile image